Santos David A's Form 4 filing
Rigel Pharmaceuticals Inc (RIGL) · filed Feb 6, 2025
- Accession no.
- 0000905148-25-000412
- Filed
- Feb 6, 2025
- Trade date
- Feb 4-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $83.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Santos David ACIK 0001820066 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2025 | Common Stock | SSaleDisposed | −2,125 | $20.92 | −$44,455 | 53,500 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −1,796 | $21.93 | −$39,386.28 | 51,704 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.